I was going to say, it looks like MSB has revised their estimated numbers, now targetting 500 children with GvHD and 5 x that..... 2500 adults.
Children,
Estimated $500,000 cost per treatment
Revenue could be up to 250 million USD from pediatric, and 1.25 billion for adults with that specific targeted group treated.
assuming 50% margin,
188 million AUD possible profit - pediatrics
944 million AUD possible profit - adults
PE 20:1 Pediatrics = Share price $3.30 AUD
PE 20:1 Pediatrics + Adults = Share price $16.61 AUD
Price today .... $1.18
Plenty of upsides here, particularly given I have not accounted for any off label use at all.
Link to the new treatment numbers
https://youtu.be/XAsqnY2dlDk?si=TYORJAlOVzyzy3vD&t=484
2024 Here we go again., page-596
-
- There are more pages in this discussion • 348 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |